<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38840773</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2688-2663</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>MedComm</Title><ISOAbbreviation>MedComm (2020)</ISOAbbreviation></Journal><ArticleTitle>Chemoproteomics enables identification of coatomer subunit zeta-1 targeted by a small molecule for enterovirus A71 inhibition.</ArticleTitle><Pagination><StartPage>e587</StartPage><MedlinePgn>e587</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e587</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/mco2.587</ELocationID><Abstract><AbstractText>Human enterovirus A71 (EV-A71) is a significant etiological agent responsible for epidemics of hand, foot, and mouth disease (HFMD) in Asia-Pacific regions. There are presently no licensed antivirals against EV-A71, and the druggable target for EV-A71 remains very limited. The phenotypic hit 10,10'-bis(trifluoromethyl) marinopyrrole A derivative, herein termed MPA-CF<sub>3</sub>, is a novel potent small-molecule inhibitor against EV-A71, but its pharmacological target(s) and antiviral mechanisms are not defined. Here, quantitative chemoproteomics deciphered the antiviral target of MAP-CF<sub>3</sub> as host factor coatomer subunit zeta-1 (COPZ1). Mechanistically, MPA-CF<sub>3</sub> disrupts the interaction of COPZ1 with the EV-A71 nonstructural protein 2C by destabilizing COPZ1 upon binding. The destruction of this interaction blocks the coatomer-mediated transport of 2C to endoplasmic reticulum, and ultimately inhibits EV-A71 replication. Taken together, our study disclosed that MPA-CF<sub>3</sub> can be a structurally novel host-targeting anti-EV-A71 agent, providing a structural basis for developing the COPZ1-targeting broad-spectrum antivirals against enteroviruses. The mechanistic elucidation of MPA-CF<sub>3</sub> against EV-A71 may offer an alternative COPZ1-involved therapeutic pathway for enterovirus infection.</AbstractText><CopyrightInformation>© 2024 The Author(s). MedComm published by Sichuan International Medical Exchange &amp; Promotion Association (SCIMEA) and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoyong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug, and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University Chengdu China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergence Drugs Beijing Institute of Pharmacology and Toxicology Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Chemistry and Molecular Engineering Peking University Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yaxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug, and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University Chengdu China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug, and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University Chengdu China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuexiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergence Drugs Beijing Institute of Pharmacology and Toxicology Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergence Drugs Beijing Institute of Pharmacology and Toxicology Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Ruiyuan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergence Drugs Beijing Institute of Pharmacology and Toxicology Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Song</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergence Drugs Beijing Institute of Pharmacology and Toxicology Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug, and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy Sichuan University Chengdu China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>College of Chemistry and Molecular Engineering Peking University Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Wu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Engineering Research Center for the Emergence Drugs Beijing Institute of Pharmacology and Toxicology Beijing China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>MedComm (2020)</MedlineTA><NlmUniqueID>101769925</NlmUniqueID><ISSNLinking>2688-2663</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chemoproteomics</Keyword><Keyword MajorTopicYN="N">coatomer subunit zeta‐1</Keyword><Keyword MajorTopicYN="N">enterovirus A71</Keyword><Keyword MajorTopicYN="N">marinopyrrole A derivate</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>6</Day><Hour>3</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38840773</ArticleId><ArticleId IdType="pmc">PMC11151152</ArticleId><ArticleId IdType="doi">10.1002/mco2.587</ArticleId><ArticleId IdType="pii">MCO2587</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nasri D, Bouslama L, Pillet S, et al. Basic rationale, current methods and future directions for molecular typing of human enterovirus. Expert Rev Mol Diagn. 2007;7(4):419‐434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620049</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308‐318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Lin T, Chiang P, et al. An investigation of epidemic enterovirus 71 infection in Taiwan, 2008. Pediatr Infect Dis J. 2010;29(11):1030‐1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">20543760</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Pan H, Liu P, et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev Med Virol. 2015;25(2):115‐128.</Citation><ArticleIdList><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Podin Y, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis. 2007;44(5):646‐656.</Citation><ArticleIdList><ArticleId IdType="pubmed">17278054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Huang KJ, et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis. 2003;188(4):564‐570.</Citation><ArticleIdList><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818‐828.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829‐837.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum‐adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2013;381(9882):2024‐2032.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent F, Nueda A, Lee J, et al. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. 2022;21(12):899‐914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9708951</ArticleId><ArticleId IdType="pubmed">35637317</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Yang J, Zou L, et al. Synthesis of 10,10′‐bis(trifluoromethyl) marinopyrrole A derivatives and evaluation of their antiviral activities in vitro. Eur J Med Chem. 2022;238:114436.</Citation><ArticleIdList><ArticleId IdType="pubmed">35598412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed S, Heck AJR, Boersema PJ, et al. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat Protoc. 2009;4(4):484‐494.</Citation><ArticleIdList><ArticleId IdType="pubmed">19300442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu J, Huang S, Chow N, et al. Stable‐isotope dimethyl labeling for quantitative proteomics. Anal Chem. 2003;75(24):6843‐6852.</Citation><ArticleIdList><ArticleId IdType="pubmed">14670044</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Wang M, Cheng A, et al. Enterovirus replication organelles and inhibitors of their formation. Front Microbiol. 2020:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7468505</ArticleId><ArticleId IdType="pubmed">32973693</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse M, Fernández DCI, Tenorio R, et al. The viral replication organelles within cells studied by electron microscopy. Adv Virus Res. 2019;105:1‐33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112055</ArticleId><ArticleId IdType="pubmed">31522702</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu NY, Ilnytska O, Belov G, et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell. 2010;141(5):799‐811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982146</ArticleId><ArticleId IdType="pubmed">20510927</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez‐Navarro N, Miller EA. COP‐coated vesicles. Curr Biol. 2016;26(2):R54‐R57.</Citation><ArticleIdList><ArticleId IdType="pubmed">26811885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Wu Z, Jin Q. COPI is required for enterovirus 71 replication. PLoS One. 2012;7(5):e38035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3360637</ArticleId><ArticleId IdType="pubmed">22662263</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunev S, Semmelink MFW, Xian JL, et al. Crystal structure of truncated human coatomer protein complex subunit ζ1 (Copζ1). Acta Crystallogr F Struct Biol Commun. 2017;73(1):1‐8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5287372</ArticleId><ArticleId IdType="pubmed">28045387</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazlauskas E, Petrauskas V, Paketurytė V, et al. Standard operating procedure for fluorescent thermal shift assay (FTSA) for determination of protein‐ligand binding and protein stability. Eur Biophys J. 2021;50(3‐4):373‐379.</Citation><ArticleIdList><ArticleId IdType="pubmed">33914114</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor RJ, Tagiltsev G, Briggs J. The structure of COPI vesicles and regulation of vesicle turnover. Febs Lett. 2023;597(6):819‐835.</Citation><ArticleIdList><ArticleId IdType="pubmed">36513395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuge O, Hara‐Kuge S, Orci L, et al. zeta‐COP, a subunit of coatomer, is required for COP‐coated vesicle assembly. J Cell Biol. 1993;123(6 Pt 2):1727‐1734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2290901</ArticleId><ArticleId IdType="pubmed">8276893</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Wang K, Zhao K, et al. The structure, function, and mechanisms of action of enterovirus non‐structural protein 2C. Front Microbiol. 2020:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767853</ArticleId><ArticleId IdType="pubmed">33381104</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang WF, Yang SY, Wu BW, et al. Reticulon 3 binds the 2C protein of enterovirus 71 and is required for viral replication. J Biol Chem. 2007;282(8):5888‐5898.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182608</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J, Liu F, Qi H, et al. Changing epidemiology of hand, foot, and mouth disease in China, 2013–2019: a population‐based study. Lancet Reg Health West Pac. 2022;20:100370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8743221</ArticleId><ArticleId IdType="pubmed">35036978</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SP, Huang YC, Li WC, et al. Comparison of clinical features between coxsackievirus A2 and enterovirus 71 during the enterovirus outbreak in Taiwan, 2008: a children's hospital experience. J Microbiol Immunol Infect. 2010;43(2):99‐104.</Citation><ArticleIdList><ArticleId IdType="pubmed">20457425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KY. Enterovirus 71 infection and neurological complications. Korean J Pediatr. 2016;59(10):395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099286</ArticleId><ArticleId IdType="pubmed">27826325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Hu Y, Zheng M. Enterovirus A71 antivirals: past, present, and future. Acta Pharm Sin B. 2022;12(4):1542‐1566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Wang Y, He W, et al. Design, synthesis, and evaluation of novel enterovirus 71 inhibitors as therapeutic drug leads for the treatment of human hand, foot, and mouth disease. J Med Chem. 2020;63(3):1233‐1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">31939669</ArticleId></ArticleIdList></Reference><Reference><Citation>De Colibus L, Wang X, Spyrou JAB, et al. More‐powerful virus inhibitors from structure‐based analysis of HEV71 capsid‐binding molecules. Nat Struct Mol Biol. 2014;21(3):282‐288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530014</ArticleId><ArticleId IdType="pubmed">24509833</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Yu J, Hao F, et al. Discovery of potent EV71 capsid inhibitors for treatment of HFMD. Acs Med Chem Lett. 2017;8(8):841‐846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554915</ArticleId><ArticleId IdType="pubmed">28835799</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Xu Z, Zhang F, et al. Identification of a novel binding inhibitor that blocks the interaction between hSCARB2 and VP1 of enterovirus 71. Cell Insight. 2022;1(2):100016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10120312</ArticleId><ArticleId IdType="pubmed">37193133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G, Ye Y, Zhang D, et al. Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure‐based virtual screening. Eur J Med Chem. 2016;124:981‐991.</Citation><ArticleIdList><ArticleId IdType="pubmed">27776325</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Musharrafieh R, Zheng M, et al. Enterovirus D68 antivirals: past, present, and future. Acs Infect Dis. 2020;6(7):1572‐1586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055446</ArticleId><ArticleId IdType="pubmed">32352280</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Xu Z, Jin M, et al. Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: in vitro, in vivo, and combination therapy study. Eur J Med Chem. 2020;202:112310.</Citation><ArticleIdList><ArticleId IdType="pubmed">32619885</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol. 1997;51:151‐178.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343347</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjuán R, Domingo‐Calap P. Mechanisms of viral mutation. Cell Mol Life Sci. 2016;73(23):4433‐4448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5075021</ArticleId><ArticleId IdType="pubmed">27392606</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schaar HM, Leyssen P, Thibaut HJ, et al. A novel, broad‐spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4‐kinase IIIβ. Antimicrob Agents Chemother. 2013;57(10):4971‐4981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811463</ArticleId><ArticleId IdType="pubmed">23896472</ArticleId></ArticleIdList></Reference><Reference><Citation>Strating JR, van der Linden L, Albulescu L, et al. Itraconazole inhibits enterovirus replication by targeting the oxysterol‐binding protein. Cell Rep. 2015;10(4):600‐615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383725</ArticleId><ArticleId IdType="pubmed">25640182</ArticleId></ArticleIdList></Reference><Reference><Citation>Duden R. ER‐to‐Golgi transport: cOP I and COP II function (Review). Mol Membr Biol. 2003;20(3):197‐207.</Citation><ArticleIdList><ArticleId IdType="pubmed">12893528</ArticleId></ArticleIdList></Reference><Reference><Citation>Anania MC, Cetti E, Lecis D, et al. Targeting COPZ1 non‐oncogene addiction counteracts the viability of thyroid tumor cells. Cancer Lett. 2017;410:201‐211.</Citation><ArticleIdList><ArticleId IdType="pubmed">28951131</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Kong Y, Ma Y, et al. Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines. Oncogene. 2021;40(8):1425‐1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906905</ArticleId><ArticleId IdType="pubmed">33420375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Y, Xia Z, Sun Y, et al. A comprehensive pan‐cancer analysis of the regulation and prognostic effect of coat complex subunit zeta 1. Genes‐Basel. 2023;14(4):889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10137353</ArticleId><ArticleId IdType="pubmed">37107648</ArticleId></ArticleIdList></Reference><Reference><Citation>Niphakis MJ, Cravatt BF. Enzyme inhibitor discovery by activity‐based protein profiling. Annu Rev Biochem. 2014;83:341‐377.</Citation><ArticleIdList><ArticleId IdType="pubmed">24905785</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CY, Li JR, Ou YC, et al. Enterovirus 71 infection caused neuronal cell death and cytokine expression in cultured rat neural cells. Iubmb Life. 2015;67(10):789‐800.</Citation><ArticleIdList><ArticleId IdType="pubmed">26399559</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Dan K, Xue X, et al. Curcumin assists anti‐EV71 activity of IFN‐α by inhibiting IFNAR1 reduction in SH‐SY5Y cells. Gut Pathog. 2022;14(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8840321</ArticleId><ArticleId IdType="pubmed">35151347</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Chen C, Tan J, et al. ERK inhibition aids IFN‐β promoter activation during EV71 infection by blocking CRYAB degradation in SH‐SY5Y cells. Pathog Dis. 2023:81.</Citation><ArticleIdList><ArticleId IdType="pubmed">37259226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KX, Chu JJ. Antiviral screen identifies EV71 inhibitors and reveals camptothecin‐target, DNA topoisomerase 1 as a novel EV71 host factor. Antivir Res. 2017;143:122‐133.</Citation><ArticleIdList><ArticleId IdType="pubmed">28427827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao T, Li Y, Fan S, et al. Design, synthesis and pharmacological evaluation of a novel mTOR‐targeted anti‐EV71 agent. Eur J Med Chem. 2019;175:172‐186.</Citation><ArticleIdList><ArticleId IdType="pubmed">31082764</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Hao P, Li L, et al. Design and synthesis of minimalist terminal alkyne‐containing diazirine photo‐crosslinkers and their incorporation into kinase inhibitors for cell‐ and tissue‐based proteome profiling. Angew Chem Int Ed Engl. 2013;52(33):8551‐8556.</Citation><ArticleIdList><ArticleId IdType="pubmed">23754342</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YG, Wang JX, Zhang GN, et al. Design, synthesis, and biological activity evaluation of a series of pleuromutilin derivatives with novel C14 side chains. Bioorg Med Chem Lett. 2020;30(7):126969.</Citation><ArticleIdList><ArticleId IdType="pubmed">32014384</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Gao J, Che J, et al. A dimethyl‐labeling‐based strategy for site‐specifically quantitative chemical proteomics. Anal Chem. 2018;90(15):9576‐9582.</Citation><ArticleIdList><ArticleId IdType="pubmed">29989794</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Xu L, He D, et al. In vivo time‐related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model. PLoS One. 2014;9(10):e109391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4184856</ArticleId><ArticleId IdType="pubmed">25279734</ArticleId></ArticleIdList></Reference><Reference><Citation>Shtutman M, Baig M, Levina E, et al. Tumor‐specific silencing of COPZ2 gene encoding coatomer protein complex subunit ζ 2 renders tumor cells dependent on its paralogous gene COPZ1. Proc Natl Acad Sci USA. 2011;108(30):12449‐12454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3145676</ArticleId><ArticleId IdType="pubmed">21746916</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu M, Yan Y, et al. Molnupiravir and its active form, EIDD‐1931, show potent antiviral activity against enterovirus infections in vitro and in vivo. Viruses. 2022;14(6):1142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9227765</ArticleId><ArticleId IdType="pubmed">35746614</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27(3):493‐497.[CrossRef]</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>